Abrocitinib 100 mg versus 200 mg for atopic dermatitis: a meta-analysis of randomized controlled trials.

Introduction: It is elusive to compare the efficacy and safety of abrocitinib 100 mg versus 200 mg once daily in patients with atopic dermatitis.
Aim: This meta-analysis aims to explore the influence of abrocitinib 100 mg versus 200 mg on the treatment of atopic dermatitis.
Material and Methods: Several databases including PubMed, EMbase, Web of science, EBSCO, and Cochrane library were systematically searched through July 2021. We included randomized controlled trials (RCTs) assessing the effect of abrocitinib 100 mg versus 200 mg for patients with atopic dermatitis.
Results: Four RCTs were included in the meta-analysis. Compared with abrocitinib 100 mg for atopic dermatitis, abrocitinib 200 mg had a remarkably positive impact on IGA response (OR = 1.78; 95% CI: 1.39-2.28; p < 0.00001), EASI-75 (OR = 2.03; 95% CI: 1.60-2.57; p < 0.00001), NRS response (OR = 1.97; 95% CI: 1.27-3.08; p = 0.003), and adverse events (OR = 1.43; 95% CI: 1.11-1.84; p = 0.005), but it showed no obvious influence on serious adverse events (OR = 0.59; 95% CI: 0.25-1.37; p = 0.22).
Conclusions: Abrocitinib 200 mg is better than abrocitinib 100 mg for the treatment of atopic dermatitis.
Competing Interests: The authors declare no conflict of interest.
(Copyright: © 2022 Termedia Sp. z o. o.)